High Technology Letters ISSN NO : 1006-6748

PALLIATIVE CARE - IMPROVING PATIENT’S QUALITY OF LIFE

Syed Fadil Mohammed 1, Shreeraam.J 1, Praveen.D 2, Ranadheer.P 2, Vijey Aanandhi.M 3

1School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.

2Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India

3Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India. .

Corresponding Author Dr. M. Vijey Aanandhi Professor and Head, Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Pallavaram, Chennai – 600117, India.

ABSTRACT:

Palliative care has been one of themaximumswiftlydeveloping fields of fitness care withinside thebeyond decade. The blessings of palliative care have now been proven in more than onescientific trials, with extendedsufferers and issuer satisfaction, identical or higher symptom control, greater discernment of and honouring picksapproximatelylocation of death, fewer and depression, much less caregiver distress, and feefinancial savings. The feefinancial savings come from fee avoidance, or motion of a affected person from aexcessivefeeputting to a decreasefee settings. Barriers to increased use encompassdoctor resistance, unrealistic expectancies of sufferers and families, and shortage of workforce. The destiny of palliative care consists ofgreater penetration into different fields together with nephrology, neurology, and surgery, in addition discernment of the simplest and fee - powerful models, and status quo of greater outpatients services.

Key words: Palliative care, supportive care, Hospice care, Cost avoidance, Medical economics

Volume 27, Issue 4, 2021 544 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

The Types of Palliative Care

Similar to oncology or cardiology care, palliative care is available in3 types . Primary palliative care is broughteach daywithinside thescientificworkplace and ought to be a part ofthe usualability set of all practitioners. It consists of symptom evaluation, religiousevaluation, powerfulconversation with “ask, tell, ask,” and dialogue of improve care making plans with transition activates to end-of-existence care. Secondary palliative care is broughtvia way of means ofspecialisedgroups at specialisedapplications or inpatient units. Such groups are interdisciplinary and bothoffer direct duty for a patient's care or functionexperts to a number one team. One instance is the palliative care clinic, that mayassistnumber one physicians throughout a huge spectrum of illnesses with things likeachecontrol and figuring outdreams of care . Tertiary palliative care is broughtvia way of means ofspecialisedgroups with knowledge in superiorache and symptom control, which include implantable intraspinal drug-transportstructures for ache, palliative sedation, or superior delirium control.[1]

Several fortecompaniestry to paintings with different practitioners to sellschoolingapproximatelynumber one palliative care; for instance, the American Society of Clinical Oncology has partnered with the American Academy of Hospice and Palliative Medicine to expand the essential competencies, curriculum, and evaluationgear for oncologists to offergiftednumber one palliative care. The cutting-edge oncology self- evaluation program, Quality Oncology Project Initiative (QOPI), has some of palliative and hospice care metrics which includevariety of sufferersmentioned hospice and the period of live in hospice . QOPI has effectivelydecreased the variety of sufferers receiving chemotherapy in thefinal weeks of existence and has progressedachecontrolwhilst its metrics are implemented in practice. [1,3]

Challenges involved in Palliative Care

Several tendencies in fitness care these dayslower the hazard of most cancerssufferersgaining access to palliative care. These variety from confined availability of palliative care offerings to the philosophy of affected person care that dominates our fitness care system. the call formost cancersofferings will increase. At the equal time, the deliver of physicians, and specifically oncologists, will lowerdue to the retirement of a massivepercent of oncologists, a lowerwithinside therange of skilled physicians, and a brand newtechnology of physicians who will choose topaintings part ‐time or in specialties with fewer running hours and much less emotional call for than the forte of oncology. The reputation and elevated use of palliative care physicians and nurse practitioners who focus on palliative care is one technique that has been advocated to deal with this staff shortage. A palliative care expert is higherorganizedto fulfillsufferers' wishesand might relieve a number ofthe load of care from

the oncologist. [2,3]

Volume 27, Issue 4, 2021 545 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

Most affected person care is sickness oriented, with a focal pointat the tumour, the remedytechnique , and fortesessionwith the aid of usingnumerousclinical disciplines. Care is generally complex, and remedyincludes many specialties. After remedy , remission accompaniedwith the aid of using recurrence and extraremedyisn't alwaysuncommonfor lotssufferers , for this reasongrowing the want for a couple of physicians and introducing ability fragmentation of the characteraffected person 's care. The want for health practitionerknowledgeoutdoor of oncology will increase, because themost cancerspopulacea while and comorbidities increase. Coordination of care throughout this many disciplines is limited. One technique to this trouble has been to apply navigators (laypersons, nurses, and social workers) to helpmost cancerssufferers as they passvia diagnosis, remedy , and follow ‐up care. [3]

Palliative care can remodel the modern-dayailment ‐targetedtechnique to a affected person ‐focused philosophy, wherein the desires of the affected person and affected person and own circle of relativesdesiresend upcritical to making plans the affected person's care. Patient ‐centeredness broadens the point of interest of care and calls forclean coordination throughout specialties and disciplines in addition toget entry toto palliative care physicians and nurses. [4]

Another issue of care this issurelymissing in modern-dayfitness care structures is verbal exchange with sufferers on their desires and alternatives for care. When sufferers are requested what sort of care they needwhilstsevere and life ‐threatening ailment occurs, their alternativesencompassache and symptom control, avoidance of prolongation of the death process, a feel of control, problem for the weightthey'llvicinity on own circle of relatives, and an possibilityto reinforce relationships with cherished ones. However, studies does now no longerdisplay that sufferers' alternatives are safely met. Moderate to intenseache has been pronouncedvia way of means of 60% of sufferers with colon most cancers and via way of means of 57% of sufferers with lung most cancersamong Days eight and 14 of hospitalization—a enoughduration after admission to get any achebelow control. Family contributorsrecordterrible emotional support, a loss of respectful treatment, and no involvement in choicesapproximately care. [3,4]

Nonopioid Analgesics Acetaminophen is analgesic and antipyretic however not anti ‐inflammatory. antecedentlythought of to be co-analgesic with opioids, and to be first ‐line medical aidwithin theolder patient with contractile organ pains or pain related to osteoarthritis, new attention has been targeted on the relative restrictedeffectuality and vital adverse effects of this agent, notablyviscus and excretory organ toxicity. This concern is combined by the inclusion of Anacin IIIduring akind of prescription opioid preparations (eg, hydrocodone or codeine) yet as in a big range of over ‐the ‐counter products. Of extra concern in those receiving cancer therapy are case reports of interactions between antineoplastic agents and Anacin IIIresulting

Volume 27, Issue 4, 2021 546 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

inviscus toxicity. Reduced doses of 2000 mg/day or the dodging of acetaminophen is usually recommendedwithin the face of insufficiency or liver failure, and notably in people with a

history of great alcohol use. [5]

Nonsteroidal anti ‐inflammatory medication (NSAIDs) manufacturephysiological state by block the biogenesis of prostaglandins, inflammatory mediators that initiate, cause, intensify, or maintain pain. These agents conjointlyseemto cut back pain through their influence on the peripheral or central systema nervosumfreelance of their anti ‐inflammatory mechanism of action, though this result remains poorly understood. The nonselective NSAIDs, corresponding toacetylsalicylic acid or ibuprofen, inhibit enzymes that convert arachidonic acid to prostaglandins and as a result, GI ulceration, excretory organ dysfunction, and impaired living substance aggregation will occur. The cyclooxygenase ‐2 (COX ‐2) accelerator pathway is elicited by tissue injury or different inflammation ‐inducing conditions and there seems to be reduced risk of GI haemorrhageonceemploying a COX ‐2 selective agent; however, this advantage seems to diminish oncehalf dozen months of use. Furthermore, taking eighty one mg of acetylsalicylic acid for cardio protection beside a COX ‐2 substanceleads to the GI ulceration risk result of a traditional, nonselective NSAID. In addition, there's a risk of vessel events, corresponding toheart muscle infarction, and vas complications, such as stroke, with prolonged use [5,6]

As a class, the NSAIDs are helpfulwithin the treatment of pain conditions mediate by inflammation, together with those caused by cancer, comparable to bone metastases. The NSAIDs do supply the potential advantage of inflictingsmallest nausea, constipation, sedation, or adverse effects on mental functioning. Therefore, reckoning on the reason for pain, NSAIDs could also be useful for the management of moderate to severe pain, sometimes as associate adjunct to opioid analgesic therapy. The addition of NSAIDs to opioids has the potential good thing about reducing the opioid dose once sedation, obtundation, confusion, dizziness, or different central systema nervosum effects of opioid analgesic therapy alone become burdensome. fadednephriticoperate and liver failure are relative contraindications for anti-inflammatory drug use. protoplasmpathology or different potential trauma disorders, common thanks to cancer or its treatment, counsel use of the nonselective NSAIDs due to their restrictive effects on platelet aggregation, with resultant prolonged bleeding time. nucleon pump inhibitors or misoprostol may be given to forestall GI bleeding. [5,7]

Opioids Opioids are vital to presentingpowerful analgesia in most cancersache . A overviewof every opioid follows. There is first rate interindividual variability in reaction to a specific agent and clinicians couldadvantage from know-how the primaryvariationsamongthose drugs. This will help in drug choice and, later, opioid rotation. Of note, there may be no proof that a selected opioid agonist is advanced to any other as first ‐line therapy. The agent that works for a specificaffected person is the “right” drug. Another component to take into

Volume 27, Issue 4, 2021 547 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

accountwhilstdeciding on an opioid is feedue to the fact high ‐feesellers can area undue burden on sufferers and families. Transdermal buprenorphine has currently been accreditedfor usewithinside the United States; it is been hiredwithinside thecontrol of most cancersache in Europe and open ‐label and randomised managed trials suggest this partial agonist is useful in relieving most cancersache . The available doses are 5, 10, and twenty μg/hour and additionally the patch is changedevery seven days. The 5‐μg/hour patch becameaccredited for opioid ‐naïve sufferers . Studies of buprenorphine advocatethere may be a ceiling end result for analgesia, proscribing the efficaciousness of this agent in palliative care. the maximumcounseled dose is 20 μg/hour due to the fact , at larger doses, QT prolongation has been observed. Most of the found outunderstanding with transdermic buprenorphine displays its use in sufferers with relatively little opioid doses; therefore, clinicians mustchorus from starting this agent in suffererswho're tolerant to strong opioids. In addition, little or noenjoy exists to signify AN bestleap forward opioid as soon as victimization transdermal buprenorphine, because of early researchhad beencarried out in Europe, anyplace organ buprenorphine is obtainable for rescue dosing. endovenous anodyne has been determined to be secure and powerful , aleven though this pathisn't alwaysrealistic for suffererswithinside thedomestic setting. a whole lot ofevaluation is needed. Buprenorphine is moreoverto be had parenterally withinside the us and sublingually, on my own or collectively with naloxone. These latter formulations are usuallyhiredwithinside

theremedy of opioid addiction. [8]

Codeine could be acomparatively weak opioid which willlean alone, thoughit'sa lot ofoftentimes administered together with Anacin III. it'son the market in oral tablets, alone or in combination with acetaminophen or different products, and as a syrup, often with promethazine. anodyne is metabolized by glucuronidation primarily to codeine ‐6‐glucuronide, and to a far lesser degree to norcodeine, morphine, morphine ‐3‐glucuronide (M ‐3‐G), morphine ‐6‐glucuronide, and normorphine. anodyne is a prodrug and shouldendure this metabolism to be reborn to its active agents. This methodis basically through the action of the accelerator CYP 2D6. The polymorphism seen during this enzyme between various ethnic groups, Associate in Nursingd between people, results ina bigproportion of patients getting reduced analgesia. around 3% of Asians and African Americans and 10% of Caucasians are poor metabolizers. These individuals would get reduced analgesic effects. In addition, some individuals are ultrarapid metabolizers, resulting inthe chance of redoubledblood serum levels and adverse effects. The death of an child whose mother was given anodynewhereas breastfeeding illustrates these safety concerns; genotyping of the mother for the CYP 2D6 acceleratorunconcealed her to be an ultrarapid metabolizer. [9]

Fentanyl may be aextremelylipide soluble opioid (partition constant 820) that may be administered parenterally, spinally, trans dermally, transmucosal, buccally, and intranasally. It can evenbe by nebulizer for the management of dyspnoea. Dosing units are typically in micrograms because of the efficiency of this opioid, and heavyissues of safety arise once these units are confused with milligrams, notablythroughoutblood vessel delivery. [10]

Volume 27, Issue 4, 2021 548 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

Hydromorphone has similar properties compared with opiate and is on the market in oral tablets, liquids, suppositories, and duct formulations. A long ‐acting formulation has been available internationally for several years and is currently available within the United States. it's extremely soluble and roughly five to ten times stiffer than morphine, and as a result, hydromorphone is employed oft once little volumes are required for endovenous or body covering infusions. analgesic undergoes glucuronidation and also the primary matter is hydromorphone ‐3‐glucuronide (H ‐3‐G). [10]

Methadone has many characteristics that build it helpful within the management of severe cancer pain. with affinity almost like ketamine. this is often believed to be of explicit profit in the relief of neuropathic pain, though a Cochrane review of existing studies found similar analgesic effects compared with morphine. In addition, conducted a irregular controlled trial in cancer patients and located no vital clinical distinction when compared with morphine. narcotic conjointly blocks re-uptake of monoamine neurotransmitter and norepinephrine, another doubtless favourable attribute in its use to treat neuropathic pain. [10]

Several of those attributes also complicate the employment of synthetic heroin. though the long half ‐life is AN advantage, it also will increase the potential for drug accumulation before achieving steady ‐state blood levels, putt patients in danger for over sedation and metabolic process depression. This may occur whena pair ofto five days of treatment with methadone and thusshutobservation of these probably adverse or maybe life ‐threatening effects is required. In addition, the acceptable dosing quantitative relation between methadone and anodyne or different opioids, similarlybecause the safest and simplest time course for conversion from another opioid to methadone, isn't known. [11]

There is nice variability within themechanics of synthetic heroin between individuals, and causes for this variability embodysupermolecule binding, CYP 3A4 activity, urinary pH, and different factors. synthetic heroin binds avidly to alpha1 glycoprotein, that is hyperbolic in advanced cancer, resulting in decreasing amounts of unbound methadone and at the start delaying the onset of effect. As a result, the interindividual variability of the pharmacology of methadone is alsoadditional pronounced in patients with cancer. [10]

Methadone is metabolized primarily by CYP 3A4, howeveradditionally by CYP 2D6 and CYP 1A2. As a result, medication that induce CYP enzymes accelerate the metabolism of methadon, leading to reduced bodily fluid levels of the drug. this could be incontestible clinically by shortened analgesic periods or reduced overall pain relief. medication that inhibit CYP enzymes slow methadone metabolism, probablyresulting in sedation and metabolism depression. Of specific concern in medical specialty care are interactions with ketoconazole, omeprazole, and selective monoamine neurotransmitteruptakematter (SSRI) antidepressants like fluoxetine, paroxetine, and sertraline. [9]

Volume 27, Issue 4, 2021 549 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

Although morphine becameformerlytaken into consideration the “gold standard,” we now understand that because of the extensive variability in response, the maximumsuitable agent is the opioid that works for a specific patient. Morphine is to be had in a extensivevariety of formulations and routes, which include oral, parenteral, and rectal delivery. The energetic metabolite of morphine, M ‐3‐G, may alsomake a contribution to myoclonus, seizures, and hyperalgesia ( growing pain), in particularwhile clearance is impaired because of renal impairment, even though this has been said to arise with hydromorphone, methadone, and fentanyl as well. [10]

Oxycodone is a artificial opioid to be had in immediate ‐release, long ‐performing , and liquid formulations. It is likewiseto be had in mixture with acetaminophen, even thoughthis mayrestrict dose escalation withinside theman or woman with most cancers . one look atevaluatingthose long ‐performing formulations in people with superiormost cancersdiscovered that oxycodone produced much less nausea and vomiting. Drug interactions can ariseamong oxycodone and sellers affecting the P450 3A4 enzyme. [11]

Oxymorphone is a semisynthetic opioid that has been to be had parenterally and as a suppository for greater than 50 years; greater recently, immediate ‐ and extended ‐launch (12 ‐hour) oral formulations were developed. [11]

Tapentadol is a brand new opioid that binds to the mu opioid receptor activation and inhibits norepinephrine reuptake. To date, no researchwereposted in most cancers pain. In differentmedical trials, there look like fewer GI detrimentaloutcomeswhilein comparison with oxycodone. [11]

Tramadol is idea to be about one ‐10th as strong as morphine in most cancerssufferers. Individuals receiving better doses of tramadol or who've a records of seizures can be at elevatedhazard for seizures. Currently to be had in immediate ‐launch and extended ‐launch formulations, the ceiling dose of tramadol is commonlytaken into consideration to be four hundred mg/day. In a double ‐blind examine of most cancerssufferers, tramadol produced greaterdetrimentaloutcomes, inclusive of vomiting, dizziness, and weakness, whilein comparison with hydrocodone and codeine. [11]

Other Opioids Meperidine and propoxyphene aren'tadvocated in most cancersachecontrolbecause of the neurotoxic resultsin their metabolites, normeperidine and nor propoxyphene, respectively. Mixed agonist ‐antagonist opioid analgesics, which include butorphanol, nalbuphine, and pentazocine, aren'tadvocated in most cancersachecontrolbecause of their ceiling impact for analgesia; they'remuch more likely to motive psychotomimetic results, and they are able to precipitate the abstinence syndrome if given to a affected personwho'sbodilydepending on a natural opioid agonist. [11,12]

Volume 27, Issue 4, 2021 550 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

Opioid‐Related Adverse Effects:

A full-sizecomponent in nonadherence to an analgesic routine is opioid ‐associatednegativeresults, specially constipation and sedation. Tolerance does now no longerincrease to constipation and consequently it ought to be averted and, if unsuccessful, handled aggressively. Most suggest a bowel routine that consists of a laxative and stool softener, consisting of senna and docusate, even though a currenthave a look atcautioned that senna by myselfchanged intosimply as effective. an opioid antagonist that works on receptors withinside the GI device and is given subcutaneously, may be used as a rescue while constipation is genuinelyassociated with opioid remedy. Sedation is regularly attributed to opioid remedy, even though many differenttabletsutilized inmost cancers care can make a contribution to this negativeimpact, which include benzodiazepines, antiemetics, and differentmarketers.[12,13]

Tolerance to opioid ‐caused sedation might also additionallyincreaseinsidesome days of everyday use; however, in a fewinstancesthis will persist and opioid rotation can be warranted. An exchangeremedy can encompass the addition of psychostimulants, consisting of methylphenidate at a dose of fiveto ten mg a couple of times daily. One have a look atdetermined that the timing of methylphenidate, which includenighttimeconsumption, did now no longer disrupt sleep. Nausea and vomiting and pruritus are greaternot unusualplace in opioid ‐naïve individuals. Around ‐the ‐clock antiemetic remedy instituted at the start of opioid remedy in the onessufferers who file nausea and vomiting with beyondconsumptionregularly prevents this negativeimpact. The antiemetic may be weaned in maximuminstances after 2 to a few days. For complex nausea and vomiting, combos of antiemetics running on one-of-a- kind receptors Other negativeresults, which includerespiration depression, are significantly feared and cause clinician below prescribing and reluctance with the aid of usingsufferers to take the medication, regardless of the rarity of this occasion in men and women with most cancers. Despite this fear, research have discovered no correlation among opioid dose, timing of opioid administration, and time of death. [13,14]

Adjuvant Analgesics:

Tricyclic antidepressants offer analgesia via inhibition of the reuptake of norepinephrine and serotonin. A currentassessment of analgesic researchperformed in neuropathic ache conditions, normally diabetic neuropathy and different noncancer conditions, decided that there may beproof for thosemarketers in imparting a clinically applicableimpact. Despite the absence of effectivemanagedmedical trials in most cancersache, the tricyclic antidepressants are normally believed to offerremedy from neuropathic ache.[12,14]

One consensus panel indexed this pharmacologic class as one in allnumerous first ‐line treatment plans for neuropathic ache. Side resultsmay be dose ‐limiting. Cardiac arrhythmias, conduction abnormalities, narrow ‐attitude glaucoma, and clinically full-size prostatic

Volume 27, Issue 4, 2021 551 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

hyperplasia are relative contraindications to the tricyclic antidepressants. Their sleep ‐improving and mood ‐raisingresultscan be of benefit. [12,13]

Conclusion:

Palliative care packages have grown swiftlywithinside the United States and the arenathanks to the aggregate of highernice of life, highernice of care, and the availability of care at an lower priced cost. The scientific and economic arguments are compelling to extend palliative care, especially with an older sicker population, and to carry outextrastudies into each symptom manage and improvement of version systems. The fundamentalboundaries will staythe shortage of staff and schoolingpackages and the insufficientinvestment for studies.[15,16]

Acknowledgment: The authors are thankful to the VISTAS and its management for providing necessary support and facilities.

References:

1. van der Plas, A., Onwuteaka-Philipsen, B., Francke, A., Jansen, W., Vissers, K. and Deliens, L., 2015. Palliative Care Case Managers in Primary Care: A Descriptive Study of Referrals in Relation to Treatment Aims. Journal of Palliative Medicine , 18(4), pp.324-331. 2. Keim-Malpass, J. and Lindley, L., 2017. End-of-Life Transitions and Hospice Utilization for Adolescents. Journal of Hospice & Palliative Nursing , 19(4), pp.376- 382. 3. Paice, J. and Ferrell, B., 2011. The management of cancer pain. CA: A Cancer Journal for Clinicians , 61(3), pp.157-182. 4. Gordon, D., Pellino, T., Miaskowski, C., McNeill, J., Paice, J., Laferriere, D. and Bookbinder, M., 2002. A 10-year review of quality improvement monitoring in pain management: Recommendations for standardized outcome measures. Pain Management Nursing , 3(4), pp.116-130. 5. Gaertner, J., Boehlke, C., Simone II, C. and Hui, D., 2019. Early palliative care and the opioid crisis: ten pragmatic steps towards a more rational use of opioids. Annals of Palliative Medicine , 8(4), pp.490-497. 6. Steins, M., Eschbach, C., Villalobos, M. and Thomas, M., 2017. Schmerztherapie in der Palliativmedizin. Pneumologie , 71(05), pp.297-306. 7. Motov, S., Strayer, R., Hayes, B., Reiter, M., Rosenbaum, S., Richman, M., Repanshek, Z., Taylor, S., Friedman, B., Vilke, G. and Lasoff, D., 2018. The

Volume 27, Issue 4, 2021 552 http://www.gjstx-e.cn/ High Technology Letters ISSN NO : 1006-6748

Treatment of Acute Pain in the Emergency Department: A White Paper Position Statement Prepared for the American Academy of Emergency Medicine. The Journal of Emergency Medicine , 54(5), pp.731-736. 8. Dijkstra, B., Berben, S., van Dongen, R. and Schoonhoven, L., 2013. Review on pharmacological pain management in trauma patients in (pre-hospital) emergency medicine in the Netherlands. European Journal of Pain , 18(1), pp.3-19. 9. Ghosh, A., Dzeng, E. and Cheng, M., 2015. Interaction of Palliative Care and Primary Care. Clinics in Geriatric Medicine , 31(2), pp.207-218. 10. Buss, M., Rock, L. and McCarthy, E., 2017. Understanding Palliative Care and Hospice. Mayo Clinic Proceedings , 92(2), pp.280-286. 11. Ghandourh, W., 2016. Palliative care in cancer: managing patients’ expectations. Journal of Medical Radiation Sciences , 63(4), pp.242-257. 12. Busolo, D. and Woodgate, R., 2015. Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports , 13(1), pp.99-111. 13. van der Velden, N., Meijers, M., Han, P., van Laarhoven, H., Smets, E. and Henselmans, I., 2020. The Effect of Prognostic Communication on Patient Outcomes in Palliative Cancer Care: a Systematic Review. Current Treatment Options in Oncology , 21(5). 14. Friedrichsen, M., Lindholm, A. and Milberg, A., 2011. Experiences of truth disclosure in terminally ill cancer patients in palliative home care. Palliative and Supportive Care , 9(2), pp.173-180. 15. Schoonover H, Corbett CF, Weeks DL, Willson MN, Setter SM. Predicting potential postdischarge adverse drug events and 30-day unplanned hospital readmissions from medi- cation regimen complexity. J Patient Saf. 2014;10(4):186-191. 16. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096- 1099.

Volume 27, Issue 4, 2021 553 http://www.gjstx-e.cn/